重编程
血管生成
病态的
癌症研究
化学
内皮干细胞
医学
人参皂苷Rg1
肿瘤细胞
基质金属蛋白酶
细胞生物学
生物
炎症
新生血管
血管生成抑制剂
内皮
作者
Haobin Li,Haocheng Deng,Jiali Liu,Qixiang Zhang,Lingge Cheng,Li Wan,Mengyuan Gao,Yujie Han,Xinping Wang,Xue Zhou,Sainan Peng,Lihua Shao,Guangji Wang,Chao Jiang,Chongjin Zhong,Fang Zhou
标识
DOI:10.1016/j.apsb.2026.09.002
摘要
ATP citrate lyase (ACLY) is a pivotal enzyme implicated in cancer cells’ aberrant survival and proliferation. However, its precise role in tumor endothelial cells (TECs) in tumor angiogenesis and malignant progression remains poorly defined. Our previous studies have identified a high distribution of ginsenoside Rd in TECs, yet the mechanism underlying its anti-angiogenic properties has not been elucidated. Here, we clarify the direct regulatory effects of ACLY in TECs and explain how Rd reprograms the ACLY metabolic pathway in TECs. Systemic Acly silencing in tumor models resulted in suppressed angiogenesis and tumor progression. Importantly, TEC-specific Acly knockdown directly disrupted pathological vascularization and exerted comparable inhibitory effects on tumor growth. Metabolomic profiling revealed that ginsenoside Rd reduced nuclear acetyl-coenzyme A (acetyl-CoA) levels by down-regulating ACLY expression, thereby inhibiting the transcription of angiogenesis-related factors through reduced acetylation of histone H3 (but not H4). Mechanistically, ginsenoside Rd promotes the ubiquitin-mediated degradation of ACLY by targeting and suppressing ubiquitin-specific peptidase 13 (USP13). This study not only establishes a mechanistic framework for the development of ACLY-centric therapeutic strategies to reprogram pathological vasculature but also identifies the natural compound Rd as a pharmacological modulator of TECs metabolism via targeting the USP13–ACLY axis.
科研通智能强力驱动
Strongly Powered by AbleSci AI